Xintela AB (publ) (XINT.ST)
SEK 0.32
(-0.63%)
SEK 0.32
(-0.63%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 78 Thousand SEK | 2.59% |
| 2022 | -3.78 Million SEK | -8.33% |
| 2021 | -3.49 Million SEK | 2.07% |
| 2020 | -3.56 Million SEK | -162.85% |
| 2019 | 5.67 Million SEK | 248.83% |
| 2018 | 1.62 Million SEK | 342.62% |
| 2017 | -671 Thousand SEK | -21.34% |
| 2016 | -553 Thousand SEK | -276.11% |
| 2015 | 314 Thousand SEK | -92.96% |
| 2014 | 4.45 Million SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 299 Thousand SEK | 134.49% |
| 2024 Q2 | 4000.00 SEK | -98.66% |
| 2023 Q1 | -936 Thousand SEK | 33.14% |
| 2023 Q4 | -867 Thousand SEK | 8.93% |
| 2023 FY | -3.68 Million SEK | 2.59% |
| 2023 Q3 | -952 Thousand SEK | -2.04% |
| 2023 Q2 | -933 Thousand SEK | 0.32% |
| 2022 Q4 | -1.4 Million SEK | -47.68% |
| 2022 Q3 | -948 Thousand SEK | -1.83% |
| 2022 Q2 | -931 Thousand SEK | 2.41% |
| 2022 Q1 | -954 Thousand SEK | -15.5% |
| 2022 FY | -3.78 Million SEK | -8.33% |
| 2021 FY | -3.49 Million SEK | 2.07% |
| 2021 Q4 | -826 Thousand SEK | 6.77% |
| 2021 Q1 | -827 Thousand SEK | 0.0% |
| 2021 Q3 | -886 Thousand SEK | 0.0% |
| 2021 Q2 | -886 Thousand SEK | -7.13% |
| 2020 FY | -3.56 Million SEK | -162.85% |
| 2020 Q1 | - SEK | -100.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2019 Q4 | 5.67 Million SEK | 283700.0% |
| 2019 Q3 | 2000.00 SEK | 0.0% |
| 2019 Q2 | - SEK | -100.0% |
| 2019 Q1 | 1000.00 SEK | -99.84% |
| 2019 FY | 5.67 Million SEK | 248.83% |
| 2018 FY | 1.62 Million SEK | 342.62% |
| 2018 Q4 | 616 Thousand SEK | -0.16% |
| 2018 Q3 | 617 Thousand SEK | 0.0% |
| 2018 Q2 | - SEK | -100.0% |
| 2018 Q1 | 395 Thousand SEK | 0.0% |
| 2017 Q4 | - SEK | -100.0% |
| 2017 FY | -671 Thousand SEK | -21.34% |
| 2017 Q1 | 1000.00 SEK | 0.0% |
| 2017 Q2 | - SEK | -100.0% |
| 2017 Q3 | 1000.00 SEK | 0.0% |
| 2016 FY | -553 Thousand SEK | -276.11% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 Q4 | - SEK | -100.0% |
| 2016 Q3 | 3000.00 SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q3 | 309 Thousand SEK | 276.83% |
| 2015 Q2 | 82 Thousand SEK | 0.61% |
| 2015 Q1 | 81.5 Thousand SEK | 0.0% |
| 2015 FY | 314 Thousand SEK | -92.96% |
| 2015 Q4 | 285 Thousand SEK | -7.77% |
| 2014 FY | 4.45 Million SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 100.049% |
| Ziccum AB (publ) | -23.28 Million SEK | 100.335% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 99.977% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 99.813% |
| Mendus AB (publ) | 28.48 Million SEK | 99.726% |
| Genovis AB (publ.) | 54 Million SEK | 99.856% |
| Intervacc AB (publ) | -13.79 Million SEK | 100.565% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 96.407% |
| Active Biotech AB (publ) | -1.67 Million SEK | 104.657% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 99.217% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 99.709% |
| Aptahem AB (publ) | 2.63 Million SEK | 97.035% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 102.28% |
| Kancera AB (publ) | -1.96 Million SEK | 103.969% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -1.299% |
| Fluicell AB (publ) | 1.73 Million SEK | 95.512% |
| Saniona AB (publ) | 11.78 Million SEK | 99.338% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 101.524% |
| Biovica International AB (publ) | 6.87 Million SEK | 98.866% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 100.335% |
| AcouSort AB (publ) | 8.38 Million SEK | 99.07% |
| Abliva AB (publ) | -35.66 Million SEK | 100.219% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 100.053% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 97.221% |
| OncoZenge AB (publ) | 3000.00 SEK | -2500.0% |
| Amniotics AB (publ) | -1.93 Million SEK | 104.041% |
| 2cureX AB (publ) | -37.48 Million SEK | 100.208% |
| CombiGene AB (publ) | -21.29 Million SEK | 100.366% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 118.44% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.993% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.995% |
| Corline Biomedical AB | 28.38 Million SEK | 99.725% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 100.064% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 100.227% |
| I-Tech AB | 27.56 Million SEK | 99.717% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 99.89% |
| Cyxone AB (publ) | 2.61 Million SEK | 97.013% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 97.708% |
| Biosergen AB | -456 Thousand SEK | 117.105% |
| Cantargia AB (publ) | -3.45 Million SEK | 102.26% |
| NextCell Pharma AB | -43.74 Million SEK | 100.178% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 100.848% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 99.305% |
| Nanologica AB (publ) | -76 Thousand SEK | 202.632% |
| SynAct Pharma AB | -778 Thousand SEK | 110.026% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 140.415% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 100.604% |
| Lipum AB (publ) | 53 Thousand SEK | -47.17% |
| BioInvent International AB (publ) | 71.46 Million SEK | 99.891% |
| Alzinova AB (publ) | 19.87 Million SEK | 99.608% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 99.785% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 94.669% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 620.0% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 95.296% |
| Simris Alg AB (publ) | 2 Million SEK | 96.114% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 102.179% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 99.78% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 107.436% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 97.51% |